These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 9053590

  • 1. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T, Morishima Y, Watanabe K, Takahashi M, Shibano T.
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [Abstract] [Full Text] [Related]

  • 2. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ, Smith CB, Rosenthal G, Lucchesi BR.
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [Abstract] [Full Text] [Related]

  • 3. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM.
    Circ Res; 1992 Jan 04; 70(1):39-48. PubMed ID: 1727687
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA, Lucchesi BR.
    J Pharmacol Exp Ther; 1983 Dec 04; 227(3):790-6. PubMed ID: 6418881
    [Abstract] [Full Text] [Related]

  • 8. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries.
    Willerson JT, Igo SR, Yao SK, Ober JC, Macris MP, Ferguson JJ.
    Tex Heart Inst J; 1996 Dec 04; 23(1):1-8. PubMed ID: 8680268
    [Abstract] [Full Text] [Related]

  • 9. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR.
    J Pharmacol Exp Ther; 1987 Feb 04; 240(2):674-82. PubMed ID: 3806419
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML, Harris DN, Heran CL, Phillips MB, Michel IM, Goldenberg HJ.
    Eicosanoids; 1988 Feb 04; 1(2):85-91. PubMed ID: 2856188
    [Abstract] [Full Text] [Related]

  • 11. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ.
    J Pharmacol Exp Ther; 1997 May 04; 281(2):677-89. PubMed ID: 9152373
    [Abstract] [Full Text] [Related]

  • 12. Vasodilator action of KB-944, a new calcium antagonist.
    Morita T, Yoshino K, Kanazawa T, Ito K, Nose T.
    Arzneimittelforschung; 1982 May 04; 32(9):1037-42. PubMed ID: 6890822
    [Abstract] [Full Text] [Related]

  • 13. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ.
    J Pharmacol Exp Ther; 1995 Jan 04; 272(1):20-32. PubMed ID: 7815334
    [Abstract] [Full Text] [Related]

  • 14. Sustained coronary constriction and its antagonism by calcium-blocking agents in monkeys and baboons.
    Taira N, Satoh K, Maruyama M, Yamashita S.
    Circ Res; 1983 Feb 04; 52(2 Pt 2):I40-6. PubMed ID: 6403259
    [Abstract] [Full Text] [Related]

  • 15. Effects of 3-methoxycyproheptadine in a canine model of coronary thrombosis.
    Bush LR, Remy DC.
    J Pharmacol Exp Ther; 1988 Nov 04; 247(2):796-802. PubMed ID: 3183974
    [Abstract] [Full Text] [Related]

  • 16. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
    Bullough DA, Zhang C, Montag A, Mullane KM, Young MA.
    J Clin Invest; 1994 Oct 04; 94(4):1524-32. PubMed ID: 7929829
    [Abstract] [Full Text] [Related]

  • 17. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765.
    Grover GJ, Parham CS, Sleph PG, Moreland S.
    J Pharmacol Exp Ther; 1989 Dec 04; 251(3):1020-5. PubMed ID: 2481028
    [Abstract] [Full Text] [Related]

  • 18. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis.
    Folts J.
    Circulation; 1991 Jun 04; 83(6 Suppl):IV3-14. PubMed ID: 2040070
    [Abstract] [Full Text] [Related]

  • 19. Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
    Beaughard M, Brasset M, John G, Massingham R.
    J Cardiovasc Pharmacol; 1995 Oct 04; 26(4):577-83. PubMed ID: 8569218
    [Abstract] [Full Text] [Related]

  • 20. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation.
    Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M.
    Thromb Haemost; 1992 Mar 02; 67(3):302-5. PubMed ID: 1641819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.